Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — FY2021 Earnings Presentation
16 slides from Xbrane Biopharma AB's earnings presentation, Feb 24, 2022
Slide 1: Xbrane Biopharma AB Year-End Report, 2021, Presentation
Xbrane Biopharma AB Year-End Report, 2021, Presentation “The agreement with Biogen confirms Xbrane as a leading global Biosimilar Developer” Martin Åmark, CEO Solna February 24th, 2021 SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Year-End Report 2021 24/02/2022
Slide 2: Disclaimer
Disclaimer You must read the following before continuing. The following applies to this document and the information provided in Company may alter. modify or otherwise change in any manner the content of this presentation. without obligation to this presentation by Xbrane Biopharma AB (publ) (the “C
Slide 3: Xbrane has a portfolio addressing €32 billion of reference product sales
Xbrane has a portfolio addressing €32 billion of reference product sales Reference Patent Sales Development Commercialization Candidate Indication Next milestone Product Expiry 2021 Phase Partner • Age-related macular degeneration Q1 2022 : US • Diabetic macular 2020/22 XlucaneTM €3.2b Registration
Slide 4: Focus for 2021
Focus for 2021 Focus for 2021 Outcome • Top-line data from Xplore Phase III study EU • Applying for market approval for XlucaneTM US Pending for Q1 2022 • Sign agreements with additional partners for the sales and Pending for 2022 marketing of XlucaneTM, primarily in China, Latin America, and Japan.
Slide 5: An expanding patent portfolio
An expanding patent portfolio Xbrane patents and patent applications (#) Key aspects of emerging IP portfolio Xbrane patents and patent applications (#) • The Swedish Intellectual Property Office (PRV) 30 granted eight patents in total in 2021 • Six patents protect the novel DNA sequences as part of
Slide 6: Ambition to be the most attractive employer within our field
Ambition to be the most attractive employer within our field Certified as a Great Place to Work® Equality Managment team No of employees +61% YoY 70 60 58 * 54 54 50 Women Men Women Women 45 40 36 Experience 50 30 International 45 20 40 35 10 30 25 0 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Foreign Sweden
Slide 7: Upcoming Capital Markets Events Spring 2022
Upcoming Capital Markets Events Spring 2022 Erik Penser 14th Kempen Life Life Science Summit Healthcare Day Sciences Conference Amsterdam February 24, 2022 April 20, 2022 May 19, 2022 13.40 CET SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Year-End Report 2021 24/02/2022
Slide 8: Year-End Report 2021, Financials
Year-End Report 2021, Financials SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Year-End Report 2021 24/02/2022
Slide 9: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Total Company Expenses decreased with close to 0 -6,1 -6 50% in the fourth quarter of 2021 -8 -8,6 -8,8 -10 Mainly driven by reclassification of XlucaneTM -20 meeting the classification criteria of IAS 38 as of -28,9 July 1st, 2021. D
Slide 10: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Comparing like for like year-on-year, total Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 0 Operating Costs have decreased with 10.4% -6,1 -8 -8,6 -8,8 -6 -10 The total R&D costs (incl. Intangible Asset of SEK -20 -28,9 22.7m) amount to SEK 51.6m, 90% of the total -36,5 costs in
Slide 11: Cash and Cash Equivalents, Shareholders' Equity
Cash and Cash Equivalents Shareholders’ Equity 450 500 462,4 400 383,4 450 431,7 350 400 295,2 350 300 243,1 239,2 300 250 257,7 249,7 250 200 208,4 200 150 129,3 150 100 100 50 50 0 0 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 At Year-end 2021, Cash amounts to 295.2 MSEK.
Slide 12: Outlook for 2022
Outlook for 2022 SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Year-End Report 2021 24/02/2022
Slide 13: Focus for 2022
Focus for 2022 Candidate Focus for 2022 • Apply for market approval in US • Obtain market approval in Europe XlucaneTM • Production of launch volume (post patent expiry of originator) • Prepare for launch (STADA and B+L) • Scale up of production process with AGC Biologics XcimzaneTM • Prepare for in
Slide 14: Xbrane is building a powerful R&D engine
Xbrane is building a powerful "R&D engine" High yield platform Diverse, qualified and State of the art lab facility technology motivated team Relative yield (g/L) (%) Xbrane team LEMO Standard 80 100% 80% 60 60% 40 40% 20% 0% + 20 0 + Membrane protein Average of Antibody fragment 16 different protei
Slide 15: Xbrane's ambition communicated at CMD May 2021
Xbrane´s ambition communicated at CMD May 2021 • Initiate one new development program per year • Partner up pre-clinically to co-fund clinical development – high return of investment as demonstrated with Biogen deal • XlucaneTM net-income of +€100m 3 years post launch • Positive operating cash-flow
Slide 16: Q&A
Q&A SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Year-End Report 2021 24/02/2022